New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:09 EDTMELAMELA Sciences initiates study on clinical impact of MelaFind on melanoma biopsy
MELA Sciences announced that it has initiated a study to examine the real-world clinical impact of MelaFind on dermatologists' decision to biopsy pigmented skin lesions that are suspicious for melanoma. CEO Rose Crane commented, "This trial is significant as the data will be based on patient assessments by dermatologists using the MelaFind system. It will provide us with a measure of the real-world clinical impact of MelaFind on melanoma diagnosis, and we believe it will support our case for insurance reimbursement. We welcome Dr. Rigel's oversight as the principal investigator of this important study."
News For MELA From The Last 14 Days
Check below for free stories on MELA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
08:29 EDTMELAMELA Sciences regains compliance with NASDAQ listing requirements
Subscribe for More Information
July 27, 2014
13:06 EDTMELAMELA Sciences closes private placement
Subscribe for More Information
July 24, 2014
08:20 EDTMELAMELA Sciences announces study results showing effectiveness of MelaFind
Subscribe for More Information
July 22, 2014
09:01 EDTMELAMELA Sciences announces $27.3M at the market private placement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use